Anti-NKG2D CAR-T cell therapy (CNK Cell Therapeutics)

N/A

Report date: 2025/06/30 16:48:05

Base Information

Drug NameAnti-NKG2D CAR-T cell therapy (CNK Cell Therapeutics)
Drug Alias NameN/A
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionAnti-NKG2-D type II integral membrane protein
TargetsNKG2-D type II integral membrane protein
Therapy Area/IndicationsSolid tumoursPancreatic Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesHangzhou CNK Therapeutics Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesCNK Cell Therapeutics Co LtdZhejiang University
Inactive CompaniesN/A
Active IndicationsSolid tumoursPancreatic Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A